Thalys Medical Technology Group Corporation (603716.SS) provides intensive medical inspection operation services, integrated IVD laboratory solutions, and medical consumables management in China. The company offers automated immunofluorescence analyzers, automatic coagulation analyzers, coagulation reagents, blood gas detection analyzers, automatic fluorescence immunoassay analyzers; intensive distribution and simple sales of in vitro diagnostic products; cooperative construction of regional testing centers; SPD services for medical consumables; and LIS/IoT solutions with full-process supply chain management. Founded in 2004 and headquartered in Wuhan, China, it primarily serves hospitals and medical institutions across the country through one-stop medical business intensification. In September 2020, the company changed its name from Thalys Medical Technology Inc. to Thalys Medical Technology Group Inc.; in September 2025, it agreed to acquire a controlling stake in an associate for CNY 70 million; it also engages in partnerships such as with Genetic Analysis AS for product launches and collaborations for thrombosis/hemostasis diagnostics.